226 related articles for article (PubMed ID: 29089174)
41. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
[TBL] [Abstract][Full Text] [Related]
42. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections.
Tacconelli E; Cataldo MA; Mutters NT; Carrara E; Bartoloni A; Raglio A; Cauda R; Mantengoli E; Luzzaro F; Pan A; Beccara LA; Pecile P; Tinelli M; Rossolini GM
Int J Antimicrob Agents; 2019 Jul; 54(1):49-54. PubMed ID: 30986523
[TBL] [Abstract][Full Text] [Related]
43. Optimizing therapy of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Gudiol C; Cuervo G; Carratalà J
Curr Opin Crit Care; 2019 Oct; 25(5):438-448. PubMed ID: 31369411
[TBL] [Abstract][Full Text] [Related]
44. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
45. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
46. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
[TBL] [Abstract][Full Text] [Related]
47. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis.
Jiang AM; Liu N; Zhao R; Zheng HR; Chen X; Fan CX; Zhang R; Zheng XQ; Fu X; Yao Y; Tian T
Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):53. PubMed ID: 33228668
[TBL] [Abstract][Full Text] [Related]
49. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
[TBL] [Abstract][Full Text] [Related]
50. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; De Cueto M; Viale P; Venditti M; Hernández-Torres A; Oliver A; Martínez-Martínez L; Calbo E; Pintado V; Gasch O; Almirante B; Antonio Lepe J; Pitout J; Akova M; Peña-Miralles C; Schwaber MJ; Tumbarello M; Tacconelli E; Origüen J; Prim N; Bou G; Giamarellou H; Bermejo J; Hamprecht A; Pérez F; Almela M; Lowman W; Hsueh PR; Navarro-San Francisco C; Torre-Cisneros J; Carmeli Y; Bonomo RA; Paterson DL; Pascual Á; Rodríguez-Baño J;
J Antimicrob Chemother; 2017 Mar; 72(3):906-913. PubMed ID: 28062685
[TBL] [Abstract][Full Text] [Related]
51. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
52. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.
Balkan II; Aygün G; Aydın S; Mutcalı SI; Kara Z; Kuşkucu M; Midilli K; Şemen V; Aras S; Yemişen M; Mete B; Özaras R; Saltoğlu N; Tabak F; Öztürk R
Int J Infect Dis; 2014 Sep; 26():51-6. PubMed ID: 24998423
[TBL] [Abstract][Full Text] [Related]
53. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
Schwaber MJ; Carmeli Y
J Antimicrob Chemother; 2007 Nov; 60(5):913-20. PubMed ID: 17848376
[TBL] [Abstract][Full Text] [Related]
54. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
Li C; Li Y; Zhao Z; Liu Q; Li B
J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
[TBL] [Abstract][Full Text] [Related]
55. Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae.
Prinapori R; Guinaud J; Khalil A; Lecuyer H; Gendrel D; Lortholary O; Nassif X; Viscoli C; Zahar JR
Am J Infect Control; 2013 Mar; 41(3):259-60. PubMed ID: 23062579
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia.
Menashe G; Borer A; Yagupsky P; Peled N; Gilad J; Fraser D; Riesenberg K; Schlaeffer F
Scand J Infect Dis; 2001; 33(3):188-93. PubMed ID: 11303808
[TBL] [Abstract][Full Text] [Related]
57. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
[TBL] [Abstract][Full Text] [Related]
58. Epidemiology and risk factors for mortality in bloodstream infection by CP-Kp, ESBL-E, Candida and CDI: A single center retrospective study.
Corcione S; Angilletta R; Raviolo S; Filippini C; Fossati L; Di Perri G; Cavallo R; De Rosa FG
Eur J Intern Med; 2018 Feb; 48():44-49. PubMed ID: 29096992
[TBL] [Abstract][Full Text] [Related]
59. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
[TBL] [Abstract][Full Text] [Related]
60. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
